Company Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 33.1% CAGR over the past five years.
Operating margin of 49.0% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.20B (+15.6% YoY); net profit $-713.41M.
- Trailing 12 Months Year-on-year growth — revenue -1.9%, earnings -403.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.06% |
| 1 Year: | -1.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -403.27% |
Stock Price Performance
| 1 Year: | +0.13% |
| 6 Months: | -21.45% |
| 3 Months: | -26.89% |
| 1 Month: | -19.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.12 · Neutral
P/E of 45.51 is above the sector median of 25.51 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 33.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 34.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRPT Sarepta Therapeutics, Inc. | 15.93 | 45.51 | $1.68B | 0.00% | -29.18% | 4.91% | 33.06% | - |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 16.34M | 35.01M | 45.95M | 57.28M | 64.60M | 73.53M | 78.49M | 84.42M | 87.01M | 94.67M | 99.04M | 100.11M | 100.45M | 111.34M | 121.43M | 122.64M | 124.93M | 141.84M | 166.91M | 188.82M | 211.24M | 207.77M | 231.50M | 238.99M | 309.32M | 359.48M | 360.55M | 429.77M | - | 744.86M | 611.09M | 399.36M | 442.93M | 730.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.56M | 152.56M | 150.78M | 398.71M | 108.77M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 308.93M | 316.00M | 338.08M | - | 607.29M | 458.53M | 248.58M | 44.23M | 622.03M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 907.68M | 342.96M | 311.46M | 454.31M | 263.60M |
| Operating Income | -51.76M | -64.45M | -59.70M | -62.10M | -56.53M | -88.39M | -39.24M | -63.34M | -45.91M | -23.15M | -30.74M | -103.43M | -70.10M | -139.36M | -76.39M | -275.37M | -123.59M | -230.22M | -118.03M | -138.35M | -137.07M | -170.72M | -151.87M | -167.57M | -34.46M | -86.88M | -211.13M | -131.35M | -138.09M | -133.52M | -20.84M | 34.91M | -701.00K | 22.20M | - | -300.39M | 115.58M | -62.88M | -410.08M | 358.43M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -369.04M | 169.71M | -168.03M | -252.20M | 375.48M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.50M | 5.23M | 7.57M | 20.84M | 21.71M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -383.52M | 153.64M | -194.05M | -278.30M | 343.17M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.99M | -43.25M | -14.10M | 4.55M | 12.21M |
| Net Income | -51.94M | -64.68M | -59.77M | -62.30M | -56.74M | -88.45M | 84.09M | -63.05M | -47.73M | -24.00M | -35.36M | -109.27M | -76.39M | -140.90M | -76.64M | -276.40M | -126.33M | -235.70M | -17.49M | -150.82M | -196.50M | -189.32M | -167.25M | -81.41M | -48.14M | -105.03M | -231.48M | -257.74M | -516.75M | -23.94M | -40.94M | 36.12M | 6.46M | 33.61M | - | -447.51M | 196.89M | -179.95M | -282.85M | 330.96M |
| Diluted EPS | - | - | -1.31 | -1.35 | - | - | 1.50 | -1.15 | -0.78 | -0.37 | -0.55 | -1.67 | - | - | - | - | - | - | - | - | - | - | - | -1.02 | -0.60 | -1.20 | -2.65 | -2.94 | -5.86 | -0.27 | -0.46 | 0.37 | 0.07 | 0.34 | - | -4.60 | 1.89 | -1.80 | -3.93 | 2.88 |
| R&D Expense | 36.67M | 41.38M | 38.83M | 44.35M | 34.35M | 70.75M | 29.12M | 58.91M | 34.24M | 44.44M | 46.20M | 122.85M | 86.58M | 146.21M | 90.55M | 113.27M | 133.95M | 223.14M | 136.14M | 188.52M | 190.44M | 207.24M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 9.76M | 1.25M | 5.42M | 154.58M | 301.03M | 380.83M | 455.87M | - | 933.01M | 1.24B | 1.90B | 2.20B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 139.99M | 150.34M | 319.10M | 839.61M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 793.02M | 1.09B | 1.58B | 1.36B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.33B | 1.36B | 1.36B | 2.02B |
| Operating Income | -15.51M | -20.93M | -35.93M | -29.70M | -90.28M | -133.79M | -220.18M | -266.73M | -171.64M | -343.63M | -705.56M | -564.16M | - | -536.20M | -267.82M | 218.08M | -657.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -594.85M | -453.69M | 316.89M | -619.56M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.25M | 22.01M | 18.39M | 38.14M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -689.96M | -520.10M | 260.77M | -702.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | -25.16M | -32.18M | -2.32M | -121.29M | -111.98M | -135.79M | -220.03M | -267.26M | -50.69M | -361.92M | -715.08M | -554.13M | - | -703.49M | -535.98M | 235.24M | -713.41M |
| Diluted EPS | -0.27 | -0.29 | -0.02 | - | - | - | - | - | - | - | - | -7.11 | - | -8.03 | -5.80 | 2.34 | -7.13 |
| R&D Expense | 24.40M | 35.97M | 66.86M | 52.40M | 72.91M | 94.23M | 146.39M | 188.27M | 166.71M | 401.84M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 1980 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 45.98M | 54.37M | 204.99M | 291.57M | 295.03M | 273.78M | 424.10M | 1.31B | 1.64B | 1.82B | 2.98B | - | 3.13B | 3.26B | 3.96B | - | 3.35B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.56B | 2.58B | 3.07B | - | 2.54B |
| Cash & Equivalents | 0 | 11.19M | 48.27M | 33.59M | 39.90M | 187.66M | 256.96M | 73.55M | 80.30M | 122.42M | 599.69M | 370.83M | 835.08M | 1.50B | - | 966.78M | 428.43M | 1.10B | - | 801.28M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 203.97M | 322.86M | 749.96M | - | 914.74M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 214.63M | 400.33M | 601.99M | - | 398.23M |
| Total Liabilities | - | - | - | - | - | 81.31M | 44.38M | 47.38M | 83.44M | 87.41M | 518.75M | 609.80M | 1.00B | 2.22B | - | 2.74B | 2.41B | 2.44B | - | 2.21B |
| Current Liabilities | - | - | - | 45.86M | 20.60M | 78.89M | 35.97M | 36.87M | 62.29M | 75.42M | 88.33M | 173.69M | 264.77M | 416.03M | - | 619.60M | 653.66M | 731.68M | - | 1.10B |
| Long Term Debt | - | - | - | 1.84M | 1.76M | 1.67M | 1.58M | 1.48M | 26.84M | 17.67M | 431.05M | 420.55M | - | - | - | 1.54B | 1.13B | 1.14B | 140.50M | 828.97M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.62B | 1.40B | 1.34B | - | 1.04B |
| Total Equity | 0 | 15.73M | 23.63M | -2.82M | 31.02M | 123.68M | 247.19M | 247.65M | 190.35M | 336.69M | 789.22M | 1.03B | 818.19M | 761.76M | - | 384.95M | 859.34M | 1.53B | - | 1.14B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.95M | 93.73M | 96.90M | - | 105.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.80M | -15.21M | -23.68M | -29.69M | -64.69M | - | - | -245.82M | -232.00M | -388.66M | -456.46M | 107.47M | - | -325.35M | -500.99M | -205.79M | -205.48M |
| Investing Cash Flow | -1.88M | -1.96M | -2.31M | -1.15M | -11.67M | - | - | -90.19M | -178.81M | -370.49M | 286.73M | -121.72M | - | -1.05B | -165.80M | 755.56M | 69.64M |
| Financing Cash Flow | 47.77M | 2.48M | 32.30M | 178.60M | 145.67M | - | - | 378.13M | 888.08M | 530.15M | 642.55M | 682.32M | - | 232.51M | 125.00M | 124.81M | -168.34M |
| Capital Expenditure | -931.00K | -832.00K | -1.18M | -108.00K | -2.37M | -25.44M | -3.40M | -5.34M | -12.00M | -61.16M | -59.63M | -82.20M | - | -32.25M | -87.34M | -146.96M | -109.85M |
| Free Cash Flow | -9.73M | -16.04M | -24.86M | -29.80M | -67.06M | - | - | -251.16M | -244.00M | -449.82M | -516.09M | 25.26M | - | -357.60M | -588.34M | -352.74M | -315.33M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.14B | -541.79M | 674.58M | -304.18M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 25.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.0% | 87.9% | 83.2% | 61.8% |
| Operating Margin % | - | - | - | - | - | -1,371.2% | -17,572.5% | -4,920.3% | -111.0% | -114.1% | -185.3% | -123.8% | - | -57.5% | -21.5% | 11.5% | -29.9% |
| Net Margin % | - | - | - | - | - | -1,391.7% | -17,560.3% | -4,930.2% | -32.8% | -120.2% | -187.8% | -121.6% | - | -75.4% | -43.1% | 12.4% | -32.5% |
| ROE % | -106.5% | 1,142.2% | -7.5% | -98.1% | -45.3% | -54.8% | -115.6% | -79.4% | -6.4% | -35.1% | -87.4% | -72.7% | - | -182.7% | -62.4% | 15.4% | -62.5% |
| ROCE % | - | -17,591.6% | -106.4% | -23.6% | -35.3% | -51.8% | -104.1% | -76.5% | -14.1% | -23.4% | -45.3% | -22.0% | - | -21.4% | -10.3% | 6.7% | -29.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.98% | 14.76M | $234.31M |
| 2 | Vanguard Portfolio Management LLC | 6.29% | 6.64M | $105.45M |
| 3 | State Street Corporation | 6.26% | 6.61M | $105.02M |
| 4 | AQR Capital Management, LLC | 6.09% | 6.43M | $102.16M |
| 5 | Two Sigma Investments, LP | 4.35% | 4.59M | $72.94M |
| 6 | Vanguard Capital Management LLC | 4.34% | 4.58M | $72.70M |
| 7 | First Trust Advisors LP | 3.92% | 4.14M | $65.68M |
| 8 | RA Capital Management, L.P. | 3.70% | 3.90M | $61.97M |
| 9 | Morgan Stanley | 2.46% | 2.60M | $41.24M |
| 10 | Erste Asset Management GmbH | 2.43% | 2.57M | $40.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SRPT
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOZWt2VnJKTkZhQVA2bDFvMVU1dl8wZmtJZDVoMHdaakc0Rks3V0dodzVQMWhtU2ZSQUZpNWs0QjNPbUhldUhFQXlreFFmbnZINHdhWFY5MlppbkJycUJRV1k1X1JJd0E1dkkxTmlKV1lTZVNMLXdJakZ2andUejdib2w2UVBLRnRSVlc1Nm…
Sarepta rises on quarterly double-line beat - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQQkk4WUpMTmp5dFdIaVhyRVFaQ016aUZ3SUNKSWRtdW1GTnpsd0dSeVZDaDVwM1hUN05ObVVtemE5UHZnM3V4RHBxemZFZ25qcEhHcXFxenNCSkdCaVpmT3Y3WWROX2VDRjhhOWJ1YXVKRUVxc2cycXRNQ0p4NVhOWVlBSTU?oc=5" targ…
Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPVzhJWWs1MFhCbDUtcnRoR2tfejI4WTFuaTJzakk3N2plWGl1ZDJTUEJ2TjZud1NTUlIxRU1jcHJTXzBSMVlCTWxNSnZ1ZC0xMmpOb2Q2bHBoOU9HNnJ6aENmeHc0OW5wQzVZMXNnNXB4b3ppbTUxRVhDUV9tTC1RQzFhVmxtTC12NlNwR2…
Vanguard Portfolio Management (SRPT) discloses 8.05% beneficial stake in Sarepta - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPVzd2aERTS3pTV0tpYzJXcjJxeFViT3ZwQm1CbHBnOXFPVW4tYWFuVWZtR0NHWmd1Qy1SY3lLM1VVTTNfR3dqRlBlZl9KMHVkbFpWTnAzbTZ0aGh3UXdwV3Z6VkxFcFhKelFsQjZqR3RBNkdmQ0t3SFhMeWJDTXdReXQ1X2dnXzVCeUhBSH…
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPcllhQWd1SGlDazhvU2YySjI2UHh0OUFUYVBNN08tT2dCTE8tZ0gtWXBFQjI4ejNQOENocWUyVkhjaTNVcDhyU3dDNDU5bWxtRjBXRDFnT3N4ZEFFMkxscnpkSzJNNnRuVkMtMjZ6VnpBbE5zS09TN3plTElTd1dpRkpzWkhLeUc5QVJzOW…
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNcUcwUjhhb0ZGUW5hQlJ0OXBzcVR1WjMxcl9OckxtNXl4SUFvU2s2MkpwZEhQMm9naVZXZmlkeDlGbFM4MjdNeFhRZDdoQWo1bVB2OFAyajNValJTYURUQTA1V2hXc3lld0d3bG1URy00SXVTNHljM0JNVEwwdWNycU9fZDJrUzA3MkdZQ2…
SRPT — Frequently Asked Questions
What is the current share price of Sarepta Therapeutics, Inc. (SRPT)?
As of 2026-08-05 17:25 PDT, Sarepta Therapeutics, Inc. (SRPT) trades at $15.93 on NasdaqGS. Its 52-week range is $14.86 to $24.45.
What is the market capitalisation of SRPT?
Sarepta Therapeutics, Inc. (SRPT) has a market capitalisation of $1.68B on NasdaqGS.
What is the P/E ratio of SRPT?
SRPT trades at a trailing price-to-earnings (P/E) ratio of 45.51. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is 1.11.
What is the return on equity (ROE) of SRPT?
SRPT has a return on equity (ROE) of 4.91%. Its return on capital employed (ROCE) is -29.18%.
Is SRPT a good stock to buy?
This page provides a data-driven analysis of Sarepta Therapeutics, Inc. (SRPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.